HealthPocket study finds copayments, coinsurance fees for drugs rise under ACA

Article

An examination of new health plans from 46 states revealed that copayments and co-insurance fees for drugs increased an average of 34% as compared to the pre-Affordable Care Act (ACA) individual insurance market.

Sunnyvale, CA-An examination of new health plans from 46 states by HealthPocket revealed that copayments and co-insurance fees for drugs increased an average of 34% as compared to the pre-Affordable Care Act (ACA) individual insurance market.

All 4 new health plan categories under the ACA had drug cost-sharing increases. Bronze health insurance plans had the highest increase, 58%, while Platinum health insurance plans had the lowest increase, 15%.

Plan enrollees who use brand-name drugs and specialty drugs face the greatest burden from the increases in copayments and co-insurance fees. Those enrollees who use medications infrequently, on the contrary, are not likely to notice the cost-sharing increases.

The 34% increase in copayments and co-insurance fees does not mean that consumers will spend 34% more on drugs. Drug spending is also affected by multiple factors including deductible amounts, out-of-pocket caps, and what drugs are included within a health plan's list of covered medications.

Prior to the ACA, nearly 1 out of 5 health insurance plans purchased privately by individuals and families lacked prescription drug coverage. In comparison, all new health plans in the individual market include a drug benefit. In addition, some over-the-counter drugs such as aspirin, folic acid, and iron supplements can be obtained without any out-of-pocket cost when used as preventive medicine.

"With copayments and co-insurance fees rising, consumers must shop health plans more carefully. Copayments, deductible amounts, and limits on annual drug spending should not be ignored," said Kev Coleman, head of research and data at HealthPocket. "Consumers can also discuss with their doctors whether there are alternative drugs that have lower costs but equivalent therapeutic results."

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.